Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Meningococcal disease is more common in the Asia-Pacific region than previously reported

Global Meningococcal Initiative
Posted on: 28 Oct 16

The Global Meningococcal Initiative (GMI) - an international group of expert scientists, doctors and public health officials - has reported today that, whilst incidence of meningococcal disease (MD) in the Asia-Pacific region appears to be low, it is likely to affect many more people in the region than existing data suggests. The GMI has made several recommendations that will reduce the public impact of meningitis in this region.

 

The GMI’s purpose is to promote the global prevention of MD, and findings from the group’s first Asia-Pacific regional meeting are published today in Vaccine: http://www.sciencedirect.com/science/article/pii/S0264410X16309380  

 

According to the report, not all doctors in this region (which incorporates India, Japan, the Republic of Korea, the Philippines) are aware of meningococcal disease and doctors who do recognise the disease often fail to report it to health authorities, perhaps due to a lack of clear guidelines or inconsistent case definitions.

 

The GMI has made several recommendations which will help reduce the devastating impact of meningococcal disease in these countries. These include: developing new guidelines to help doctors diagnose the disease; undertaking studies to determine which age groups “carry” the bacteria harmlessly in their noses and throats, thus spreading the infection around the population; improving management of outbreaks by vaccinating vulnerable groups; and promoting awareness of MD among health professionals, public health officials and the general public. 

 

Confederation of Meningitis Organisations (CoMO) and Meningitis Research Foundation (MRF)  partner with the GMI, and Linda Glennie, Head of Research at MRF welcomed the recommendations: “These are sound recommendations and they mirror what MRF calls for. Our partnership with GMI allows us to tackle MD on a global level to protect people everywhere. Meningitis does not respect borders and we’re proud to be working alongside GMI for a world free from meningitis and septicaemia.”   

 

Although currently MD is under-reported in this region, the expert group did note that serogroup A disease was most prominent in low-income countries, such as India and the Philippines, while Taiwan, Japan and Korea reported disease due to serogroups A, B and W.

 

Notes to editors

·         The Global Meningococcal Initiative (GMI) is a global expert group of over 50 scientists, clinicians, and public health officials with a wide range of specialties. The purpose of the initiative is to promote the global prevention of meningococcal disease (MD) through education, research, and cooperation.

 

·         MRF and CoMO partner with the GMI, and Chris Head, President of CoMO, is a Steering Group member of GMI.

 

·         MRF hosts a dedicated section on its website to introduce the work of GMI and to showcase the research conducted by the GMI network: www.meningitis.org/gmi.

 

·         GMI is funded by Sanofi Pasteur through an educational grant.

For more information:
www.meningitis.org/gmi

Editor's Details

Samantha Williams
Meningitis Research Foundation
www.meningitis.org/gmi
0333 405 6251
samanthaw@meningitis.org

Last updated on: 28/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.